๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers

โœ Scribed by J. Longmore; J. L. Berry; E. Szabadi; C. M. Bradshaw


Publisher
Springer
Year
1990
Tongue
English
Weight
607 KB
Volume
39
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


EPILIMยฎ CHRONO: A MULTIDOSE, CROSSOVER C
โœ D. Roberts; D. Easter; G. O'Bryan-Tear ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 446 KB

The pharmacokinetic properties and relative bioequivalence of two formulations of the antiepileptic Epilimm were compared in a three-period, repeat dose, randomized crossover study in 18 male volunteers. A daily dose of 1000 mg of antiepileptic was given either as twice-daily entericcoated sodium va

Bioequivalence of two oral formulations
โœ Marilyn Lockyer; Saleh Al-Dgither; Eman Al-Gaai; Ahmed Yousuf; Muhammad M. Hamma ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 80 KB ๐Ÿ‘ 2 views

## Purpose: The purpose of this randomized, crossover study was to compare the bioavailability of a generic and an innovator formulation of nizatidine 300 mg capsules under fasting conditions. ## Methods: Twenty blood samples per period were collected from 20 healthy, arab male volunteers over 16

Comparative class 1 electrophysiologic a
โœ Lennart Bergfeldt; Karin Schenck-Gustafsson; Rune Dahlqvist ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› Springer US ๐ŸŒ English โš– 860 KB

During steady-state treatment with disopyramide, its main and active metabolite, mono-N-dealkylated disopyramide, was reported to reach concentrations that were equal to or higher than the parent drug in 25% of 70 evaluated patients. This metabolite has been found to have a more pronounced anticholi

Comparative pharmacokinetics and pharmac
โœ Sonia Guimont; Dr Hรฉlรจne Landriault; Keith Klischer; Michael Grace; Chantal Lamb ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 586 KB

CardizemOSR and Bi-TildiemO were both approved in their respective countries on the basis of clinical trials demonstrating efficacy and safety in the treatment of angina pectoris. In this cross-over randomized study, we assessed whether these two sustained-release formulations of diltiazem have equi